Zeo ScientifiX Awards Substantial Restricted Stock to CEO/CFO and CMO
ZEOX has more than doubled off its 52-week low of $1.2 on light trading volume (0.3× avg).
Summary
Zeo ScientifiX, Inc. granted 350,000 restricted shares, valued at $923,300, to its CEO/CFO and CMO, representing a substantial amount of equity and potential dilution.
Key Events · Executive and Board Changes · ZEOX
-
Significant Restricted Stock Grant
Zeo ScientifiX awarded a total of 350,000 restricted shares to its CEO/CFO, Ian Bothwell, and CMO, Dr. George Shapiro, under its 2021 Incentive Stock Plan.
-
Substantial Dilution Potential
The shares are valued at approximately $923,300 based on the current stock price, representing a substantial amount of the company's equity and potential dilution for existing shareholders.
-
Executive Incentive and Retention
The awards vest 50% on the eight-month anniversary and the remaining 50% on the one-year anniversary, serving as a long-term incentive for key management.
Analysis · ZEOX · Life Sciences
The award of 175,000 restricted shares to both the Chief Executive Officer/Chief Financial Officer and the Chief Medical Officer represents a substantial compensatory event for Zeo ScientifiX. Valued at approximately $923,300 based on the current stock price, this grant introduces significant potential dilution for existing shareholders by granting a substantial amount of the company's equity. While such grants are intended to incentivize and retain key executives, the magnitude of this award for a company of Zeo ScientifiX's size warrants close attention from investors regarding its impact on shareholder value and future equity structure.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.6% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZEOX was trading at $2.64 on OTC in the Life Sciences sector, with a market capitalization of approximately $17.3M. The 52-week trading range was $1.20 to $3.81. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.